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In Zoccarato et al. (Zoccarato et al. 2015), we provide
extensive evidence that inhibition of PDE2 counteracts
cardiac myocyte hypertrophic growth. By measuring cell
size, nuclear NFAT-translocation, protein synthesis, pro-
tein to DNA ratio and expression of hypertrophic
markers, we demonstrate that pharmacological inhibition
of PDE2, unlike inhibition of PDE3 or PDE4, inhibits
the hypertrophy induced by norepinephrine (NE); and
that overexpression of PDE2, but not overexpression
of PDE4 or PDE3 isoforms, is sufficient to induce hy-
pertrophic growth. We show that the effect of pharma-
cological inhibition of PDE2 is recapitulated by its ge-
netic knock down (KD) using siRNA. We further dem-
onstrate that the effect of PDE2 KD is specific as the
phenotype can be rescued by overexpression of a
siRNA-insensitive PDE2 construct. In addition, we find
that overexpression of a catalytically inactive version of
PDE2 also counteracts hypertrophy, an effect that is due
to displacement of localised active endogenous PDE2.
We confirm the anti-hypertrophic effect of PDE2 inhibi-
tion both in neonatal and adult ventricular myocytes and
both in rat and mouse models. Crucially, we demon-
strate in vivo that pharmacological inhibition of PDE2
counteracts hypertrophy in a mouse model of pressure
overload and that in vivo overexpression of PDE2-
mCherry, but not of its catalytically inactive mutant,
induces cardiac hypertrophic growth in rat cardiac
myocytes. Based on the above evidence, we suggest
that inhibition of PDE2 may represent a novel therapeu-
tic approach to control cardiac hypertrophy.
Indeed, our findings are difficult to reconcile with the
observation, reported by Mehel et al., that overexpres-
sion of PDE2 in adult rat ventricular myocytes reduces
the cellular hypertrophy induced by in vitro treatment
with NE (Mehel et al. 2013). We suggested (Zoccarato
et al. 2015) that this discrepancy may be only apparent
and could be explained by the fact that in Mehel et al.,
the effect of PDE2 overexpression in NE-treated cells
was presented as relative to the effect of overexpression
of PDE2 in the absence of any additional stimulus.
Such normalisation of the data prevents evaluation of
the effect of PDE2 overexpression per se. In Wagner
et al. (Wagner et al. 2016), the authors present the same
data where now the effect of overexpression of PDE2 is
shown relative to the effect of overexpression of GFP
alone. They make the point that, in their hands, there is
no evidence of a pro-hypertrophic effect of PDE2 over-
expression; and propose that other factors, including dif-
ferences in the constructs, in the transfected PDE2 iso-
form or in its cellular localisation may explain the
discrepancy.
While there are indeed three different isoforms of PDE2
(PDE2A1, PDE2A2 and PDE2A3) for which a different
subcellular localisation has been described (Lobo and
Zaccolo 2016), this cannot account for the difference in
the results that we are discussing here as in both studies
the same isoform, PDE2A2, was overexpressed.
Other differences in the constructs and/or protocols, how-
ever, may be involved. Mehel et al. expressed PDE2A2 using a
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bicistronic adenovirus encoding EGFP (Ad-PDE2-GFP). This
results in the expression of PDE2A2 and EGFP as separate
entities, whereas, in Zoccarato et al., a single fusion protein
(PDE2A2-RFP or PDE2A2-mCherry) was overexpressed. In
addition, in Mehel et al., after isolation, the myocytes were
infected for 24 h before application of NE for additional
24 h. In Zoccarato et al., the myocytes were exposed to the
virus and simultaneously treated with NE for a total of 24 h in
culture (Fields et al. 2015). As a result, a different level of
transgene expression may be expected with the two protocols.
This may be particularly relevant when considering that over-
expression of GFP alone has been shown to induce hypertro-
phy in a dose-dependent manner (Huag et al., Nature
Medicine, 2000), and the longer the myocytes are allowed in
culture after infection, the higher the risk that this non-specific
hypertrophic effect may occur. If overexpression of GFP in-
duces per se myocyte hypertrophy, the additional effect of
overexpression of PDE2 may be more difficult to detect. We
noticed that in Fig. 2A, Wagner et al. expressed the effect of
PDE2 overexpression as relative to overexpression of EGFP. It
would be interesting to know how the size of cells overexpress-
ing EGFP compares to control non-infected cells. In Zoccarato
et al., we overexpressed a non-tagged versions of PDE2A2
(Zoccarato et al. 2015) and found a significant pro-
hypertrophic effect compared to non-infected cells. Where a
red fluorescent protein tagged PDE2 was overexpressed in
Zoccarato et al., to mitigate the potential confounding effect
of overexpression of the fluorophore we compared the effect of
overexpressing PDE2A2 with the overexpression of its cata-
lytically inactive mutant, two constructs, that except for two
point mutations in the enzyme catalytic site, are otherwise
identical and give similar levels of transgene expression
(Stangherlin et al. 2011). We found that only the wild type,
but not inactive enzyme, induced cardiac myocyte hypertrophy
(Zoccarato et al. 2015).
In our hands, both overexpression of mCherry-tagged and
of un-tagged versions of PDE2A2 results in hypertrophy
(Fig. 1). There is a smaller pro-hypertrophic effect on overex-
pression of un-tagged PDE2A2 compared to overexpression
of the mCherry-tagged variant. However, one should keep in
mind that the efficiency of viral infection is not 100%, and the
lack of a fluorescent marker makes it impossible to identify
the cells that express the transgene from those that do not. As a
consequence, a number of non-infected (and therefore non-
hypertrophic) cells are included in the calculation of the aver-
age size in the experiment with un-tagged PDE2A2. In our
system, it seems unlikely that expression of the fluorescent
protein mCherry may induce hypertrophy per se, as cells ex-
pressing the catalytically inactive PDE2A2cd-mCherry are
indistinguishable from control, non-infected cells.
In conclusion, our extensive data from both in vitro and
in vivo experiments and results from both enhancement and
inhibition of PDE2 activity, all concur in identifying PDE2A
as a hypertrophic foe. Future work, including experiments
using transgenic and KO mice, will certainly further contrib-
ute to clarify the role of PDE2 in cardiac pathophysiology.
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Fig. 1 a Cell surface area measured for control adult rat ventricular
myocytes (non-transduced) and myocytes transduced in vitro with
AdV5/PDE2Awt or AdV5/PDE2A catalytically dead (Zoccarato et al.
2015). b Cell surface area measured for control myocytes and myocytes
transduced with AdV5/PDE2Awt-mCherry or AdV5/PDE2A
catalytically dead-mCherry. Data are expressed as mean ± s.e.m. and
are the summary of three independent experiments (number of cells
analysed ≥25). One-way ANOVA and Tukey’s multiple comparison tests
were performed. **p ≤ 0.01; ***p ≤ 0.005
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